although i invariant ab and i'd like to give you a brief overview of my

article new modalities the cancer treatment or non small cell lung cancer focus on the

mean of their p

in this article i review new immune based strategies that are being developed for the

treatment of lung cancer which differ from conventional into cancer therapies

chemotherapy and target agents at directly on the chamber

most targeted agents in actively mutated proteins that give proved advantage to the tumour

or a lot and that inhibit each you have receptor tire a stink i next

and chris a native inhibit the l chi nice activity to prevent growth signalling

that the system at points that jeff secreted by the tumour stopping blood vessel formation

and starving the tumour

tumours can dampen the body's natural immune response and i'm you know therapies are designed

to increase the patient's own immune response to the chamber

one approach is that use of tumour antigen vaccines

many vaccines for lung cancer have reached the phase two or three trial stage of

development

another approach to counteract tumour really did you know suppression is we use of them

you checkpoint inhibitors

i mean chuck my pathways are used by the immune system to slow down or

prepared t cell responses

two of these pathways that have been the most heavily studied or the c t

l a for and p d one have ways

the immune checkpoint inhibitors under clinical study today are designed to prevent signaling through these

pathways to restore anti tumour responses

one c t l a for on the t cell lines it's like and on

an antigen presenting sell the t cell becomes deactivated and does not mountain immune response

to the tumour

however in the presence of an anti c t l a for immune checkpoint inhibitor

c t l a for is prevented from binding that's like in and the t

cell becomes activated

this t cell can now participate and then anti cancer immune response

similarly when p d one and at some points it's like in on the tumour

the t cell becomes deactivated

however in the presence of an anti pt one immune checkpoint inhibitor p one is

prevented from binding that's like in and the t cell becomes activated and can release

side a lyric molecules to kill the tumour

one t c t l a for me and checkpoint inhibitor if the luma map

is approved for the treatment of advanced melanoma and has shown anti cancer activity and

phase two trials of lung cancer

there are several p d one halfway agents and development

some targeting p d one and others targeting one of its like against p d

l one

no volume at a fully human and two p d one i mean checkpoint inhibitor

has reported the most data to date and shows promising activity and lung cancer

health care provider should be aware that in addition to traditional responses on conventional treatment

responses have been observed with them you know therapies

these are likely due to the immune mechanisms of action and include delayed responses or

decrease tumour burden after an initial increase

also side effects seen with the mean checkpoint inhibitors include adverse events that may be

a be related in each are

these select a ease may require more frequent monitoring and or unique intervention

dermatological gastrointestinal and the crane eighties or among the most commonly reported

although most are low grade select the ease can occur with rapid onset and prompt

medical attention is critical to their management

in the article i provide some key strategies that have been used for management of

these eight using clinical studies

to conclude my article provides an overview of the exciting them you know therapies that

are in development for lung cancer